Yet another biotech that can't operationalize cell therapy manufacturing, coming behind similar actions by Takeda, ReNeuron, Arsenal Biosciences and Novo Nordisk.
Investors continue to struggle with the realities of timelines in biologics for development, manufacturing and commercialization. Cell therapy works but the business model doesn't, at least thus far.
Investors continue to struggle with the realities of timelines in biologics for development, manufacturing and commercialization. Cell therapy works but the business model doesn't, at least thus far.